975 results match your criteria Lupus Erythematosus Drug-Induced


Periodontal health and gingival diseases and conditions on an intact and a reduced periodontium: Consensus report of workgroup 1 of the 2017 World Workshop on the Classification of Periodontal and Peri-Implant Diseases and Conditions.

J Periodontol 2018 Jun;89 Suppl 1:S74-S84

Division of Periodontology, Niigata University Graduate School of Medical and Dental Sciences, Japan.

Periodontal health is defined by absence of clinically detectable inflammation. There is a biological level of immune surveillance that is consistent with clinical gingival health and homeostasis. Clinical gingival health may be found in a periodontium that is intact, i. Read More

View Article

Periodontal health and gingival diseases and conditions on an intact and a reduced periodontium: Consensus report of workgroup 1 of the 2017 World Workshop on the Classification of Periodontal and Peri-Implant Diseases and Conditions.

J Clin Periodontol 2018 Jun;45 Suppl 20:S68-S77

Division of Periodontology, Niigata University Graduate School of Medical and Dental Sciences, Japan.

Periodontal health is defined by absence of clinically detectable inflammation. There is a biological level of immune surveillance that is consistent with clinical gingival health and homeostasis. Clinical gingival health may be found in a periodontium that is intact, i. Read More

View Article

Photodermatoses in skin of color.

J Eur Acad Dermatol Venereol 2018 Jun 10. Epub 2018 Jun 10.

Department of Dermatology, Henry Ford Hospital, Detroit, MI.

Photodermatoses represent a heterogeneous collection of disorders unified by the characteristic of being provoked through exposure to ultraviolet radiation. Generally, these conditions are classified into the following categories: immunologically mediated photodermatoses, chemical- and drug-induced photosensitivity, photoaggravated dermatoses, and photosensitivity associated with defective DNA repair mechanisms or chromosomal instabilities. The list of photodermatoses is extensive and each individual photodermatosis is understood to a different extent. Read More

View Article
June 2018
1 Read

Prevalence of antinuclear antibodies in hidradenitis suppurativa.

Int J Rheum Dis 2018 May;21(5):1018-1022

Division of Rheumatology, School of Medicine and Health Sciences, Ideas to Health Laboratory, The George Washington University, Washington, District of Columbia, USA.

Aim: The purpose of this study was to investigate the prevalence of antinuclear antibody (ANA) positivity in a cohort of patients with hidradenitis suppurativa (HS), and to assess the frequency of seroconversion during treatment with tumor necrosis factor (TNF)-α inhibitor therapy.

Methods: This prospective study was conducted through the Wound Etiology and Healing (WE-HEAL) Study. Immunofluorescence ANA testing was performed at baseline, and repeated when clinically indicated. Read More

View Article
May 2018
3 Reads

Drug-induced lupus erythematosus: an update on drugs and mechanisms.

Authors:
Ye He Amr H Sawalha

Curr Opin Rheumatol 2018 Jun 4. Epub 2018 Jun 4.

Division of Rheumatology, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA.

Purpose Of Review: Rapid introduction of newly developed drugs in the absence of clear understanding of the pathophysiologic mechanisms behind drug-induced lupus erythematosus (DILE) can sometimes make DILE difficult to recognize in clinical practice. The purpose of this review is to summarize drugs most recently reported to be involved in DILE and discuss the current landscape of diverse mechanisms involved.

Recent Findings: A large number of proton pump inhibitor (PPI)-induced subacute cutaneous lupus erythematosus cases have been reported, suggesting a shift over time in the spectrum of drugs implicated in DILE. Read More

View Article
June 2018
1 Read

Clindamycin-induced Maculopapular Exanthema with Preferential Involvement of Striae Distensae: A Koebner phenomenon?

Acta Dermatovenerol Croat 2018 Apr;26(1):61-63

Benigno Monteagudo-Sánchez, MD, Hospital Arquitecto Marcide, Avenida Residencia SN , 15405 Ferrol (A Coruńa), A Coruńa, Spain;

Clindamycin is a lincomycin-derived antibiotic useful for the treatment of anaerobic and Gram-positive aerobic bacterial infections. Cutaneous adverse reactions are usually maculopapular exanthemas, although hypersensitivity syndrome, acute generalized exanthematous pustulosis, and Stevens-Johnson syndrome have also been reported (1). We report the case of a patient with a maculopapular rash triggered by clindamycin who developed cutaneous lesions on striae distensae (SD). Read More

View Article
April 2018
3 Reads

Drug-induced Subacute Cutaneous Lupus Erythematosus Caused by a Topical Beta Blocker - Timolol.

Acta Dermatovenerol Croat 2018 Apr;26(1):44-47

Monika Bilewicz-Stebel, MD Department of Internal Medicine, Dermatology and Allergology, Curie-Skłodowskiej 10, 41-800 Zabrze, Poland, School of Public Health Medical University of Silesia in Katowice 40-027 Katowice, Poland;

Drug-induced lupus erythematosus (DI-LE) is an autoimmune condition secondary to a recent pharmacological intervention. There are no established specific diagnostic criteria for DI-LE, and the disease is recognized based on the medical history of the patient. Typically, the onset is closely related to a recent drug exposure, and the disease terminates after discontinuation of the inducing factor. Read More

View Article
April 2018
2 Reads

Bone marrow as a target organ of systemic lupus erythematosus: analysis of cases with myelofibrosis.

Int J Rheum Dis 2018 May 19;21(5):1049-1059. Epub 2018 Apr 19.

Division of Rheumatology, Department of Internal Medicine, Eskişehir Osmangazi University, Eskişehir, Turkey.

Aim: Cytopenia in the course of systemic lupus erythematosus (SLE) may be due to multiple factors. In this study, we aimed primarily to evaluate the detailed results of bone marrow (BM) biopsies of SLE patients, secondly to determine the myelofibrosis (MF) frequency and thirdly to compare BM morphologic findings as well as the clinical and laboratory parameters between groups (with MF and without MF) in cytopenic SLE patients.

Methods: We retrospectively analyzed 224 SLE patients' files. Read More

View Article
May 2018
1 Read

Rare case of chorea-hyperglycaemia-basal ganglia (C-H-BG) syndrome.

BMJ Case Rep 2018 Apr 17;2018. Epub 2018 Apr 17.

Department of Diabetes and Endocrinology, University Hospital Llandough, Llandough, UK.

An 83-year-old woman presented with acute-onset haemichorea and haemiballism particularly affecting the left side of the body. She was known to have type 2 diabetes, which was poorly controlled with sitagliptin. She was hyperglycaemic but not ketotic or acidotic. Read More

View Article
April 2018
2 Reads

The interaction between environmental triggers and epigenetics in autoimmunity.

Authors:
Bruce Richardson

Clin Immunol 2018 Jul 9;192:1-5. Epub 2018 Apr 9.

Department of Internal Medicine, Division of Rheumatology, University of Michigan, SRB 3007, 109 Zina Pitcher Pl., Ann Arbor, MI 48109-2200, United States. Electronic address:

Systemic lupus erythematosus flares when genetically predisposed people encounter environmental agents that cause oxidative stress, such as infections and sunlight. How these modify the immune system to initiate flares is unclear. Drug induced lupus models demonstrate that CD4+ T cells epigenetically altered with DNA methylation inhibitors cause lupus in animal models, and similar T cells are found in patients with active lupus. Read More

View Article
July 2018
1 Read

The devil's in the dosing: severe drug-induced liver injury in a hydroxychloroquine-naive patient with subacute cutaneous lupus erythematosus and porphyria cutanea tarda.

Lupus 2018 Jul 9;27(8):1383-1386. Epub 2018 Apr 9.

1 Division of Rheumatology, University of Michigan Medical School, USA.

A 29-year-old woman with a 1.5 year history of photosensitive skin lesions on her hands presented with a malar rash, bullous lesions on her hands, and was diagnosed with subacute lupus erythematosus after serologies revealed a positive antinuclear antibody test (1:2560), and antibodies to Ro/SSA and dsDNA. Hydroxychloroquine (400 mg/day) was prescribed and the patient developed severe drug-induced liver injury. Read More

View Article
July 2018
1 Read

Hydralazine-associated vasculitis: Overlapping features of drug-induced lupus and vasculitis.

Semin Arthritis Rheum 2018 Jan 12. Epub 2018 Jan 12.

Division of Immunology, Department of Internal Medicine, University of Iowa Hospitals and Clinics, 200 Hawkins Drive, Iowa City, IA 52242.

Introduction: Hydralazine is an antihypertensive medication that has been associated with drug-induced lupus erythematosus (DIL) as well as ANCA-associated vasculitis (AAV). Although rare, early diagnosis is critical since drug cessation is the mainstay of therapy. This retrospective study aims to characterize the clinical, laboratory, and histopathologic features of this disease. Read More

View Article
January 2018
4 Reads

Drug-induced Rowell syndrome, a rare and difficult to manage disease: A case report.

Exp Ther Med 2018 Jan 23;15(1):785-788. Epub 2017 Nov 23.

Department of Ophthalmology, Grigore T. Popa University of Medicine and Pharmacy, 700715 Iași, Romania.

Rowell syndrome is defined as the association between lupus erythematosus, erythema multiforme-like lesions and characteristic immunological changes including positive tests for rheumatoid factor, speckled antinuclear antibody, positive anti-Ro or anti-La antibodies. The present report presents the case of a 45-year-old female patient who was previously diagnosed in January 2010 with terbinafine-induced subacute cutaneous lupus erythematosus and was admitted for a skin eruption consisting of erythematous-papular erythema multiforme-like lesions, primarily on the trunk and limbs. The associated symptoms consisted of fatigability, myalgia and gonalgia. Read More

View Article
January 2018
3 Reads

ANA-Negative Hydralazine-Induced Pericardial Effusion.

Case Rep Med 2017 17;2017:3521541. Epub 2017 Dec 17.

Department of Cardiology, Maricopa Integrated Health System, Phoenix, AZ, USA.

This case describes a patient with pericardial effusion as a phenomenon of the drug-induced lupus erythematosus (DILE) syndrome due to hydralazine. The relevance of this case report lies in the fact that although hydralazine has been a known causative agent of DILE, its presentation may involve a negative anti-nuclear antibody (ANA) study. Pericardial effusion is a documented adverse effect as a result of hydralazine use. Read More

View Article
December 2017
2 Reads

Drug-induced aseptic meningitis: a mini-review.

Fundam Clin Pharmacol 2018 Jun 9;32(3):252-260. Epub 2018 Mar 9.

Centre Régional de Pharmacovigilance, CHRU de Nancy, Hôpital Central, 29, avenue du Maréchal de Lattre de Tassigny, 60034, 54035, Nancy, France.

Aseptic meningitis associates a typical clinical picture of meningitis with the absence of bacterial or fungal material in the cerebrospinal fluid. Drug-induced aseptic meningitis (DIAM) may be due to two mechanisms: (i) a direct meningeal irritation caused by the intrathecal administration of drugs and (ii) an immunologic hypersensitivity reaction to a systemic administration. If the direct meningeal irritation allows a rather easy recognition, the immunologic hypersensitivity reaction is a source of challenging diagnostics. Read More

View Article
June 2018
2 Reads

Drug-induced lupus erythematosus secondary to pirfenidone.

Br J Dermatol 2018 Jun 6;178(6):1437-1438. Epub 2018 Apr 6.

Dermatology Department, St. Vincent's University Hospital, Elm Park, Dublin 4, Dublin, Ireland.

View Article
June 2018
1 Read

Drug-Induced by Systemic Lupus Erythematosus Presenting as Recurrent Pericardial Effusion After Mitral Valve Repair.

Acta Med Iran 2017 Sep;55(9):597-601

Department of Cardiac Surgery, Imam Ali Hospital, Kermanshah University of Medicine, Kermanshah, Iran.

We report a patient presented with recurrent pericardial effusion caused by drug-induced systemic lupus Erythematosus (SLE) following mitral valve repair. The surgery was complicated by hemiparesis and convulsion in early postoperative period. The patient had been received carbamazepine for a paroxysmal seizure that occurred following mitral valve repair. Read More

View Article
September 2017
5 Reads

[Esomeprazol-induced cutaneous lupus erythematosus].

Z Gastroenterol 2017 Sep 12;55(9):861-865. Epub 2017 Sep 12.

Klinik für Gastroenterologie und gastrointestinale Onkologie, Georg-August-Universität Göttingen Universitätsmedizin, Göttingen, Germany.

Proton pump inhibitors are among the most commonly used drugs worldwide. They are considered to be largely safe and cause little side-effects. We report a 69-year-old woman who suffered from erythematous plaques 2 months after initiating therapy with esomeprazole. Read More

View Article
September 2017
1 Read

Drug-Induced Lupus Erythematosus Associated with Antiretroviral Therapy in a Patient with Human Immunodeficiency Virus: A Case Report.

Cureus 2017 Sep 7;9(9):e1661. Epub 2017 Sep 7.

Rheumatology, Mount Sinai Icahn School of Medicine Queens Hospital New York.

Antiretroviral medications are the mainstay of human immunodeficiency virus (HIV) therapy and some have been in use for over 20 years. To date, there have been no reported cases of antiretroviral therapy (ART) induced drug-induced lupus erythematosus (DILE). We present a case of a 35-year-old woman who received a combination of emtricitabine, rilpivirine, and tenofovir disoproxil fumarate for HIV treatment. Read More

View Article
September 2017
1 Read

[Secukinumab-induced subacute-cutaneous lupus erythematosus].

Hautarzt 2018 Jan;69(1):64-66

Klinik und Poliklinik für Dermatologie, Venerologie und Allergologie, Universitätsklinikum Essen, Hufelandstr. 55, 45122, Essen, Deutschland.

We report about a 52-year-old woman with onset of drug-induced lupus erythematosus (DILE) in sun-exposed areas, under therapy with secukinumab. Topical therapy with a steroid class 3 for 4 weeks showed substantial improvement. The systemic therapy was switched to ustekinumab. Read More

View Article
January 2018
2 Reads

Neutrophil extracellular traps in vasculitis, friend or foe?

Curr Opin Rheumatol 2018 Jan;30(1):16-23

Department of Medical and Health Sciences.

Purpose Of Review: Neutrophil extracellular traps (NETs) can be found at the sites of vascular lesions and in the circulation of patients with active small vessel vasculitis. Neutrophils from vasculitis patients release more NETs in vitro, and NETs have properties that can harm the vasculature both directly and indirectly. There are several ways to interfere with NET formation, which open for new therapeutic options. Read More

View Article
January 2018
2 Reads

Detailed features of hematological involvement and medication-induced cytopenia in systemic lupus erythematosus patients: single center results of 221 patients.

Eur J Rheumatol 2017 Jun 11;4(2):87-92. Epub 2017 Apr 11.

Division of Rheumatology Department of Internal Medicine, Eskişehir Osmangazi University, Eskişehir, Turkey.

Objective: Systemic lupus erythematosus (SLE) may affect a number of systems, with the hematological system being one of the most common. Our aim is to determine the existence of cytopenia at diagnosis or during follow-up of our SLE patients as well as the associated factors.

Material And Methods: A cohort of SLE patients that had been followed-up in the Department of Rheumotology from 1998 to 2015 was retrospectively assessed. Read More

View Article
June 2017
3 Reads

The impact of biological treatments on the anti-dsDNA and anti-nucleosome tests.

Lupus 2018 Jan 6;27(1):40-48. Epub 2017 Jun 6.

1 Immunology and Allergology Laboratory Unit, S. Giovanni di Dio Hospital, Florence, Italy.

Background Anti-double stranded DNA antibodies are a very heterogeneous group of antibodies, quite specific for systemic lupus erythematosus. Newer technologies, such as addressable laser bead immunoassays (ALBIA), show great potential as a diagnostic application. The production of anti-double stranded DNA antibodies is often encountered in inflammatory arthritis; however, literature reports that the actual onset of drug induced lupus in patients treated with biological drugs is a rare event. Read More

View Article
January 2018
2 Reads

Ultrastructural deposits appearing as "zebra bodies" in renal biopsy: Fabry disease?- comparative case reports.

BMC Nephrol 2017 May 12;18(1):157. Epub 2017 May 12.

Nephropathology Service, Federal University of Triângulo Mineiro, Praça Manoel Terra, 330, Uberaba, MG, CEP: 38015-050, Brazil.

Background: Fabry Disease (FD) is a genetic disorder caused by alpha-galactosidase A deficiency. Certain drugs, such as hydroxychloroquine, can produce renal deposits that mimic morphological findings seen in FD, characterizing a type of drug-induced renal phospholipidosis.

Case Presentation: Case 1: A 28-year-old female patient with systemic lupus erythematosus who had been using hydroxychloroquine for 14 months presented subnephrotic proteinuria. Read More

View Article
May 2017
8 Reads

Drug-induced cutaneous lupus erythematosus after immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy: a case series.

J Peripher Nerv Syst 2017 Sep;22(3):213-218

Department of Neurology, Academic Medical Center, Amsterdam, The Netherlands.

We describe six patients with cutaneous lupus erythematosus (cLE) during immunoglobulin G (IgG) treatment. Five patients were diagnosed with chronic inflammatory demyelinating polyneuropathy (CIDP) and one patient with possible CIDP. Five patients received intravenous immunoglobulin (IVIg) and one patient received subcutaneous immunoglobulin (SCIg). Read More

View Article
September 2017
4 Reads

Hydroxychloroquine-induced erythroderma.

Indian J Pharmacol 2017 Jan-Feb;49(1):132-134

Department of Pathology, Kasturba Medical College, Manipal University, Mangalore, Karnataka, India.

Erythroderma is characterized by diffuse erythema and scaling of the skin involving more than 90% of the total body skin surface area. Drug-induced erythroderma has rarely been reported with hydroxychloroquine. We report a case of a 50-year-old female patient, with systemic lupus erythematosus, who developed itchy lesions all over the body 1 month after starting treatment with hydroxychloroquine. Read More

View Article
December 2017
5 Reads

Guidelines on the management of drug-induced immune and secondary autoimmune, haemolytic anaemia.

Br J Haematol 2017 04 3;177(2):208-220. Epub 2017 Apr 3.

Department of Haematology, Leeds Teaching Hospitals, Leeds, UK.

View Article
April 2017
1 Read

Persistent Afebrile Abdominal Pain: An Unusual Case of Segmental Colitis in an Immunocompromised Host.

Cureus 2017 Feb 16;9(2):e1033. Epub 2017 Feb 16.

4th Internal Medicine Department, "Evangelismos" General Hospital, Athens, Greece.

In this report we describe a case of a 66-year-old woman who presented with right upper quadrant abdominal pain and bloody diarrhea. A workup revealed immunodeficiency, an immunologic profile with low complement levels resembling systemic lupus erythematosus, and a circumferential colonic wall lesion located in the ascending colon. After endoscopy and biopsy, the mass lesion was attributed to "double hit" diffuse large B-cell lymphoma, categorized as high grade large B-cell non-Hodgkin lymphoma according to the most recent revised 2016 World Health Organisation classification and considered to be a rare and highly aggressive tumor. Read More

View Article
February 2017
2 Reads

Eculizumab in secondary atypical haemolytic uraemic syndrome.

Nephrol Dial Transplant 2017 03;32(3):466-474

Department of Nephrology, Instituto de Investigación Hospital 12 de Octubre (imas12), Madrid, Spain.

Background: Complement dysregulation occurs in thrombotic microangiopathies (TMAs) other than primary atypical haemolytic uraemic syndrome (aHUS). A few of these patients have been reported previously to be successfully treated with eculizumab.

Methods: We identified 29 patients with so-called secondary aHUS who had received eculizumab at 11 Spanish nephrology centres. Read More

View Article
March 2017
11 Reads

Topical drug-induced subacute cutaneous lupus erythematosus isolated to the hands.

Lupus Sci Med 2017 13;4(1):e000207. Epub 2017 Mar 13.

The Ronald O. Perelman Department of Dermatology, New York University School of Medicine, New York, New York, USA; Division of Rheumatology, Department of Medicine, New York University School of Medicine, New York, New York, USA.

Subacute cutaneous lupus erythematosus (SCLE) is a well-defined subtype of lupus erythematosus, characterised by photosensitivity, annular and/or psoriasiform lesions, variable systemic involvement and presence of circulating SSA/anti-Ro antibodies. SCLE may be idiopathic or drug-induced. Both the idiopathic and drug-induced forms of SCLE are analogous in their clinical, serological and histological features. Read More

View Article
March 2017
5 Reads

An update in drug-induced subacute cutaneous lupus erythematosus.

Dermatol Online J 2017 Mar 15;23(3). Epub 2017 Mar 15.

Department of Dermatology, University of Utah School of Medicine, Salt Lake City, Utah.

Background: It has been over three decades sincethe first report of drug-induced subacute cutaneouslupus erythematosus (DI-SCLE) was described. Withan increasing variety of implicated drugs and thepotential for publication bias, we must consider: 1) hasthere been a change in drugs most often reported inDI-SCLE over time, and, 2) if so, of which drugs shouldclinicians be most suspicious in the setting of possibleDI-SCLE?

Objective: To determine which drug(s) present thehighest risk for inducing DI-SCLE.

Methods: The PubMed database was queried forreports of DI-SCLE from August, 2009 until May,2016. Read More

View Article
March 2017
1 Read

Annular Elastolytic Giant Cell Granuloma Successfully Treated With Adalimumab Subsequently Complicated by Drug-Induced Lupus.

J Drugs Dermatol 2017 Feb;16(2):169-171

We report a 51-year-old female with a 3-year history of recalcitrant annular elastolytic giant cell granuloma (AEGCG) who was effectively treated with the anti-tumor necrosis factor (TNF)-alpha antibody, adalimumab. Her disease was refractory to topical glucocorticoids, intralesional glucocorticoids, narrow-band ultraviolet light (UV)-B phototherapy and cyclosporine. During her treatment with adalimumab she developed a positive anti-nuclear-antibody and double-stranded-DNA antibody and her treatment was terminated. Read More

View Article
February 2017
17 Reads

Aromatase inhibitors induced autoimmune disorders in patients with breast cancer: A review.

J Adv Res 2016 Sep 23;7(5):719-726. Epub 2016 Apr 23.

Department of Medical Oncology, Ioannina University Hospital, S. Niarchos Avenue, 45500 Ioannina, Greece.

Subacute cutaneous lupus erythematosus (SCLE) is characterized by particular cutaneous manifestations such as non-scaring plaques mainly in sunlight exposed parts of the body along with specific serum autoantibodies (i.e. antinuclear antibodies (ANA), Ro/SSa, La/SSb). Read More

View Article
September 2016
2 Reads

The "red face": Not always rosacea.

Clin Dermatol 2017 Mar - Apr;35(2):201-206. Epub 2016 Oct 27.

Department of Dermatology, Andreas Syggros Hospital, University of Athens, 5, Dragoumi str, Athens, 16121, Greece. Electronic address:

Facial erythema (the "red face") is a straightforward clinical finding, and it is evident even to the untrained eye; however, a red face does not represent a single cutaneous entity. It may be due to a plethora of distinct underlying conditions of varying severity, including rosacea, demodicosis, dermatomyositis, lupus erythematosus, allergic contact dermatitis, drug-induced erythema, and emotional blushing. In clinical practice, dermatologists do not encounter only one type of facial erythema but rather a number of different shades of red. Read More

View Article
November 2017
2 Reads

Gastrointestinal system manifestations in juvenile systemic lupus erythematosus.

Clin Rheumatol 2017 Jul 16;36(7):1521-1526. Epub 2017 Feb 16.

Department of Pediatrics, Division of Rheumatology, Hacettepe University Faculty of Medicine, Sıhhiye, 06100, Ankara, Turkey.

Systemic lupus erythematosus (SLE) is an autoimmune disease which may involve gastrointestinal system (GIS). The aim of this study was to present GIS manifestations of pediatric SLE patients. The medical files of 69 children with SLE followed between January 2011 and January 2016 were reviewed. Read More

View Article
July 2017
5 Reads

Hydralazine Induced Lupus Syndrome Presenting with Recurrent Pericardial Effusion and a Negative Antinuclear Antibody.

Case Rep Rheumatol 2017 17;2017:5245904. Epub 2017 Jan 17.

Department of Internal Medicine, Seton Hall University School of Health and Medical Sciences, Saint Francis Medical Center, Trenton, NJ, USA.

Drug induced lupus erythematosus (DIL or DILE) is an autoimmune disorder caused by chronic use of certain drugs. We report a unique case of hydralazine induced lupus syndrome (HILS) with a negative antinuclear antibody in a female patient who was on hydralazine for a period of 1.5-2 years and developed recurrent pericardial effusion as a result of it. Read More

View Article
January 2017
2 Reads

A case of lupus-like syndrome in a patient receiving adalimumab and a brief review of the literature on drug-induced lupus erythematosus.

J Clin Pharm Ther 2017 Jun 12;42(3):363-366. Epub 2017 Feb 12.

Department of Dermatology and Venereology, Medical Faculty and Teaching Hospital Pilsen, Charles University, Pilsen, Czech Republic.

What Is Known And Objective: Drug-induced lupus erythematosus occurs with some drugs and resolves with their withdrawal. Anti-TNF therapies have been found to be associated with a lupus-like syndrome, which is clinically distinct from classical drug-induced as well as idiopathic lupus erythematosus.

Case Description: We describe a case of a patient with severe psoriasis, who developed muscle pain with paraesthesia accompanied by ANA titres elevation with adalimumab treatment. Read More

View Article
June 2017
2 Reads

Subacute Cutaneous Lupus Erythematosus: Clinical Characteristics, Disease Associations, Treatments, and Outcomes in a Series of 90 Patients at Mayo Clinic, 1996-2011.

Mayo Clin Proc 2017 03 6;92(3):406-414. Epub 2017 Feb 6.

Department of Dermatology, Mayo Clinic, Rochester, MN. Electronic address:

Objective: To characterize the clinical presentation, laboratory studies, disease associations, and treatments of subacute cutaneous lupus erythematosus (SCLE).

Patients And Methods: A retrospective review of 90 patients with SCLE at Mayo Clinic from January 1, 1996, through October 28, 2011, was performed.

Results: The mean patient age at diagnosis was 61 years; 64 patients (71%) were women, and 11 cases (12%) were drug induced (1996-2000, no drug-induced cases; 2001-2005, 2 cases; 2006-2011, 9 cases). Read More

View Article
March 2017
1 Read

Successful treatment of donor-derived hepatitis C viral infection in three transplant recipients from a donor at increased risk for bloodborne pathogens.

Transpl Infect Dis 2017 Apr 22;19(2). Epub 2017 Feb 22.

Division of Gastroenterology and Hepatology, Thomas Jefferson University, Philadelphia, PA, USA.

We report here the successful treatment of hepatitis C virus (HCV) transmitted from a nucleic acid testing (NAT)-negative donor to three HCV-negative recipients-two renal transplants and one liver. Both renal recipients underwent standard deceased-donor renal transplantation with immediate graft function. The liver recipient underwent standard orthotopic liver transplantation and recovered uneventfully. Read More

View Article
April 2017
3 Reads

[Recommendation for the prevention and treatment of non-steroidal anti-inflammatory drug-induced gastrointestinal ulcers and its complications].

Authors:

Zhonghua Nei Ke Za Zhi 2017 Jan;56(1):81-85

Non-steroidal anti-inflammatory drugs (NSAIDs) are a broad class of non glucocorticoid drugs which are extensively used in anti-inflammatory, analgesic, and antipyretic therapies. However, NSAIDs may cause many side effects, most commonly in gastrointestinal(GI) tract. Cardiovascular system, kidney, liver, central nervous system and hematopoietic system are also involved. Read More

View Article
January 2017
2 Reads

Nuclear Factor Erythroid 2-related Factor 2 Deficiency Exacerbates Lupus Nephritis in B6/lpr mice by Regulating Th17 Cell Function.

Sci Rep 2016 12 12;6:38619. Epub 2016 Dec 12.

Institute of Human Virology, Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, China.

Lupus nephritis (LN) is the major clinical manifestation of systemic lupus erythematosus. LN is promoted by T helper 17 (Th17) cells, which are the major pro-inflammatory T cell subset contributing to autoimmunity regulation. Nuclear factor erythroid 2-related factor 2 (NRF2) is critical for suppressing reactive oxygen species (ROS) and relieving oxidant stress by regulating antioxidant gene expression. Read More

View Article
December 2016
1 Read

Rare Occurrence of Drug Induced Subacute Cutaneous Lupus Erythematosus with Leflunomide Therapy.

J Clin Diagn Res 2016 Oct 1;10(10):OD06-OD07. Epub 2016 Oct 1.

Intern, Department of Medicine, Pt. BD Sharma PGIMS , Rohtak, Haryana, India .

Leflunomide is an immunomodulatory drug exhibiting anti-inflammatory, anti-proliferative and immunosuppressive effects. It has been widely used for treatment of active rheumatoid arthritis. Despite its good safety profile cutaneous side effects like alopecia, eczema, pruritis and dry skin have been reported with Leflunomide use. Read More

View Article
October 2016
6 Reads

Isoniazid Induced Lupus Presenting as Oral Mucosal Ulcers with Pancytopenia.

J Clin Diagn Res 2016 Oct 1;10(10):OD03-OD05. Epub 2016 Oct 1.

Professor, Department of Pulmonary Medicine, D.Y. Patil Medical College and Hospital , Mumbai, Maharashtra, India .

Drug Induced Lupus Erythematous (DILE) is a rare adverse reaction to a large variety of drugs including Isoniazid (INH), with features resembling idiopathic Systemic Lupus Erythematosus (SLE). Diagnosis require identification of a temporal relationship between drug administered and symptom. It is an idiosyncratic reaction, with no pre-existing lupus. Read More

View Article
October 2016

Treatment of antiviral-resistant recurrent erythema multiforme with dapsone.

Dermatol Ther 2017 Mar 18;30(2). Epub 2016 Nov 18.

Department of Dermatology, University of Alabama at Birmingham, Birmingham, AL.

Recurrent erythema multiforme (REM) is a chronic disease characterized by frequent episodes of target cutaneous lesions in an acral distribution. Conventional treatment includes systemic corticosteroids and antiviral therapy. The aim of this study was to evaluate dapsone as a potential steroid sparing-agent for the treatment of REM after a failed trial of at least one antiviral therapy (acyclovir, famciclovir, or valacyclovir). Read More

View Article
March 2017
3 Reads

Drug-induced cutaneous lupus erythematosus: 88 new cases.

Eur J Dermatol 2017 Feb;27(1):28-33

Department of Dermatology and Allergy Centre, Odense University Hospital, DK-5000, Odense C, Denmark.

Background: An increasing number of drugs have been linked to drug-induced subacute cutaneous lupus erythematosus (DI-SCLE). The recognition and management of DI-SCLE can be challenging, as the condition may be triggered by different classes of drugs after variable lengths of time.

Objectives: To determine the proportion of patients with cutaneous lupus erythematosus (CLE) whose drugs are an inducing or aggravating factor. Read More

View Article
February 2017
1 Read

TNF-alpha antagonist induced lupus on three different agents.

Postgrad Med 2017 Mar 28;129(2):304-306. Epub 2016 Oct 28.

c Department of Gastroenterology , Lenox hill Hospital , New York , NY , USA.

Tumor necrosis factor alpha (TNF alpha) antagonists are biologic agents used in the management of inflammatory conditions such as rheumatoid arthritis, seronegative spondyloarthropathies and inflammatory bowel disease. These agents have been recently shown to cause a syndrome called anti-TNF induced lupus (ATIL), a rare condition which has similar clinical manifestations to idiopathic systemic lupus erythematosus (SLE). Given that extra-intestinal manifestations of inflammatory bowel disease include arthritis, it can be difficult to separate arthritis due to underlying disease from drug-induced arthritis. Read More

View Article
March 2017
4 Reads

Wilson's Disease with Systemic Lupus Erythematosus.

J Assoc Physicians India 2016 Apr;64(4):81-82

Professor and Head, Department of General Medicine, Coimbatore Medical College Hospital, Coimbatore, Tamil Nadu.

Case reports of Wilson's disease occurring in combination with SLE are rarely reported in literature. Drug induced lupus have been observed in patients taking D-penicillamine for Wilson's disease. Here we report a case from Coimbatore Medical College hospital, who presented with fever and neuropsychiatric symptoms as the initial manifestation and found to have both SLE and Wilson's disease on subsequent evaluation. Read More

View Article
April 2016
3 Reads